痤疮药物市场价值预计将从 2022 年的 77.7456 亿美元增长到 2030 年的 118.0229 亿美元。预计 2022 年至 2030 年期间市场复合年增长率将达到 5.40%。CAGR of 5.40% from 2022 to 2030.
市场洞察和分析师观点:
本报告中介绍的痤疮药物市场预测可以帮助该市场的利益相关者制定增长战略。痤疮是一种常见的皮肤病,其特征是皮肤上出现粉刺(黑头和白头)、丘疹、脓疱、结节和囊肿。它通常发生在面部、颈部、胸部、背部和肩部。它主要是由油脂分泌过多、毛囊堵塞、细菌和炎症等因素引起的。痤疮的严重程度各不相同,从偶尔出现的轻微爆发到可能导致疤痕和心理困扰的严重持续性病症。有各种药物和治疗方法可以有效治疗痤疮。然而,痤疮药物的副作用阻碍了市场的增长。此外,痤疮药物市场趋势包括对有机和天然治疗的需求激增。comedones (blackheads and whiteheads), papules, pustules, nodules, and cysts on the skin. It typically occurs on the face, neck, chest, back, and shoulders. It is primarily caused by factors such as excess oil production, clogged hair follicles, bacteria, and inflammation. Acne can vary in severity, ranging from mild occasional breakouts to severe, persistent conditions that can lead to scarring and psychological distress. Various medications and treatments are available to manage acne effectively. However, side effects associated with acne medication hinder the market growth. Moreover, the acne medication market trends include an upsurge in the need for organic and natural treatments.
增长动力和限制因素:
严重痤疮通常以疼痛的囊肿、结节和持续的炎症为特征,是一种相当大的挑战,会严重影响人们的生活质量。根据 2022 年 GBD 研究,痤疮的患病率为 9.4%,在全球最常见的疾病中排名第八。寻常痤疮影响了 85% 以上的 12-25 岁年轻人。如此高的患病率导致对针对中度至重度痤疮的有效痤疮药物的需求激增。随着人们寻求减轻与严重痤疮相关的身体和情感负担的方法,对先进且更有效的处方药和非处方药治疗的需求也相应增加。这一趋势促使制药公司专注于开发创新配方,包括外用类维生素 A、口服抗生素、激素疗法和先进的外用治疗,以满足严重痤疮患者的复杂需求。 《皮肤病药物学杂志》(JDD)估计,痤疮治疗每年给美国经济带来超过 10 亿美元的直接成本,其中非处方痤疮药物占该成本的近 10%。JDD 还估计,未来几年将有数十亿美元用于痤疮治疗。因此,严重痤疮患病率的上升和相关经济成本的上升扩大了痤疮药物市场的规模。
另一方面,许多传统和全身性痤疮治疗,包括口服抗生素、类维生素 A 和激素疗法,都与一系列潜在的不良反应有关,包括皮肤干燥、刺激、光敏性、胃肠道不适,以及在极少数情况下更严重的全身副作用。这些潜在的不良反应引起了患者和医疗保健提供者的担忧,导致他们不愿采用某些痤疮药物,尤其是长期使用。副作用还导致治疗依从性不足,因为个人可能会因为无法忍受或不良的副作用而选择停止或避免使用特定药物。因此,消费者倾向于优先考虑疗效同时尽量减少不良反应的先进配方和治疗方式,从而不断需要新的、更耐受和耐受性更好的痤疮药物。因此,与痤疮药物相关的副作用限制了痤疮药物市场的增长。
定制研究以满足您的需求
我们可以优化和定制标准产品无法满足的分析和范围。这种灵活性将帮助您获得业务规划和决策所需的准确信息。
痤疮药物市场:
复合年增长率(2022 - 2030 年)5.40%- 2022 年市场规模
77.7 亿美元 - 2030 年市场规模
118 亿美元
市场动态
- 財政部
- 財政部
- 財政部
- 財政部
- 財政部
- 財政部
- 財政部
- 財政部
- 財政部
关键人物;主力;重要一员
- 梯瓦制药工业有限公司
- 梅恩制药集团有限公司
- 阿尔米拉尔公司
- 强生公司
- 太阳制药工业有限公司
- 博士伦保健公司
- CV 国际科斯米亚特里亚中心
- Galderma SA、辉瑞公司
- 葛兰素史克公司、Viatris Inc
区域概况
- 北美
- 欧洲
- 亚太
- 南美洲和中美洲
- 中东和非洲
市场细分
- 类视黄酸
- 过氧化苯甲酰
- 抗生素
- 水杨酸
- 其他的
- 外用药物和口服药物
- 处方药和非处方药
- 非炎症性痤疮和炎症性痤疮
- 示例 PDF 通过定性和定量分析展示了内容结构和信息的性质。
趋势:
随着人们越来越意识到传统护肤品中使用的合成成分和化学物质可能带来的有害影响,全球对更安全、更温和、更环保的天然和有机替代品的需求正在上升。消费者越来越多地寻求不含刺激性化学物质、人工香料和潜在刺激性物质的产品,选择利用植物成分、植物提取物、精油和其他以护肤功效而闻名的天然化合物的配方。为了响应这一趋势,许多护肤品牌和制造商正在开发各种天然和有机痤疮治疗产品,以满足注重健康的消费者的需求。这些产品通常含有茶树油、金缕梅、芦荟、绿茶提取物和水杨酸等来自天然来源的成分,提供更全面、更可持续的痤疮治疗方法,同时不影响疗效。 2022 年 7 月,有机护肤品公司 MÁDARA 推出了两款全新天然日常护肤产品——一款平衡微生物组的保湿霜和一款不干燥的洁面乳。该公司声称,这些产品是将科学与自然相结合而开发的,经过专门配制,可为不同肤色、容易长粉刺的人提供温和的护理。这两款产品均采用天然、有机和纯素成分制成——北杜松干细胞、发酵多糖、地衣和马黛茶提取物——专门针对瑕疵,保护皮肤不受伤害。成人和青少年都可以使用这款产品。因此,人们对天然和有机痤疮治疗方案的日益偏爱预计将在未来几年继续塑造痤疮药物市场的未来。
报告细分和范围:
痤疮药物市场分析考虑了以下几个部分:治疗类别、配方、类型、痤疮类型和分销渠道。根据治疗类别,市场细分为类视黄酸、过氧化苯甲酰、抗生素、水杨酸等。根据配方,市场分为外用药物和口服药物。根据用途,痤疮药物市场分为处方药和非处方药。根据痤疮类型,痤疮药物市场分为非炎性痤疮和炎性痤疮。根据分销渠道,市场分为药房和药店、零售店和电子商务。就地理分布而言,痤疮药物市场分为北美(美国、加拿大和墨西哥)、欧洲(德国、法国、意大利、英国、俄罗斯和欧洲其他地区)、亚太地区(澳大利亚、中国、日本、印度、韩国和亚太其他地区)、中东和非洲(南非、沙特阿拉伯、阿联酋和中东和非洲其他地区)以及南美洲和中美洲(巴西、阿根廷和南美洲和中美洲其他地区)。
节段分析:
2022 年,类维生素 A 占据了痤疮药物市场的最大份额(按治疗类别计算)。预计同一细分市场在 2022-2030 年期间的市场复合年增长率将显著提高。类维生素 A 只能凭医生处方购买,主要成分为维生素 A;其作用机制与视黄醇相似,但在治疗痤疮方面比后者效力更强、效果更好。类维生素 A 有口服胶囊和外用药两种形式。维甲酸、阿达帕林和异维甲酸是众所周知的类维生素 A;异维甲酸的口服制剂有时被称为 Roaccutane。类维生素 A 的外用剂量通常为每公斤患者体重 0.1-1%,口服剂量为每公斤患者体重 0.5-1 毫克。
根据配方,痤疮药物市场分为外用药物和口服药物。2022 年,外用药物占据了痤疮药物市场的较大份额。预计同一细分市场将在 2022 年至 2030 年期间实现显著的复合年增长率。外用制剂在控制和治疗痤疮方面发挥着至关重要的作用,可将活性成分直接定向输送到受影响的皮肤区域。各种类型的外用痤疮药物包括凝胶、乳霜、乳液、泡沫和溶液,每种药物都针对特定的痤疮问题和皮肤类型量身定制。这些配方通常含有类视黄酸、过氧化苯甲酰、水杨酸和抗生素等成分,每种成分在对抗痤疮爆发方面都发挥着不同的作用。
根据类型,市场分为处方药和非处方药。处方药部分在 2022 年占据了更大的痤疮药物市场份额。皮肤科医生或医疗保健提供者通常在对个人的痤疮类型、严重程度和对之前治疗的反应进行全面评估后开药。处方痤疮药物包括一系列选择,包括局部治疗、口服药物、联合疗法和针对特定痤疮问题量身定制的专门配方。处方药旨在为患有中度至重度痤疮的个人提供有针对性的有效解决方案。
按分销渠道划分,痤疮药物市场分为零售店、药房和药店,以及其他基于模式的市场。2022 年,药房和药店占据了最大的市场份额。药房和药店凭借其可及性、隐私性和可负担性(与私人医生相比)成为医疗服务、用品和知识的重要来源。近年来,药房和药店因其通过帮助管理各种疾病和医疗状况来增进健康的能力而在许多国家获得了认可。药房和药店通常拥有知识渊博的员工,可根据个人皮肤类型和问题指导顾客选择合适的痤疮药物。
区域分析:
痤疮药物市场报告的地理范围包括北美、欧洲、亚太地区、中东和非洲以及南美洲和中美洲。2022 年,北美占据全球痤疮药物市场的最大份额。
痤疮是一种由碎屑、油脂、皮脂和死皮细胞堵塞毛囊引起的皮肤病。根据美国皮肤病学会的数据,痤疮是美国最常见的疾病,每年有多达 5000 万美国人患有痤疮,是美国最常见的皮肤病。由于美国人痤疮发病率的增加以及随后各种创新痤疮药物的推出,美国的痤疮药物市场预计将扩大。此外,人们对个人美容、皮肤健康和外观的日益关注也刺激了对痤疮药物的需求。技术进步和研究促进了具有更高疗效和最小副作用的创新痤疮治疗产品的开发,进一步促进了美国痤疮药物市场的增长,因为这个国家的人们更愿意投资于能够带来理想效果的高质量产品。
预计 2022-2030 年期间,亚太地区的痤疮药物市场复合年增长率最高。中国是该地区最大的痤疮药物市场。中国痤疮药物市场的发展受到多种因素的推动。值得注意的是,人工智能远程医疗的广泛采用彻底改变了皮肤病护理,改善了治疗机会并提供了更好的个性化治疗。AIDERMA 是中国首个全包式皮肤病人工智能辅助诊断和治疗平台。咨询、教育以及诊断和治疗支持是 AIDERMA 的主要产品。提供 90 多种常见皮肤病的辅助诊断和治疗。据称这是一种提供诊断和潜在治疗方案的简单程序。超过 7,000 名临床医生已注册 AIDDA,该应用程序允许中国医生诊断牛皮癣、湿疹和特应性皮炎。
痤疮药物市场报告范围
报告属性 | 细节 |
---|---|
2022 年市场规模 | 77.7 亿美元 |
2030 年市场规模 | 118亿美元 |
全球复合年增长率(2022 - 2030 年) | 5.40% |
历史数据 | 2020-2021 |
预测期 | 2023-2030 |
涵盖的领域 | 按治疗类别
|
覆盖地区和国家 | 北美
|
市场领导者和主要公司简介 |
|
- 示例 PDF 通过定性和定量分析展示了内容结构和信息的性质。
行业发展和未来机遇:
根据公司新闻稿,全球痤疮药物市场知名参与者的不同举措如下:
- 2023 年 9 月,Cosmo Pharmaceuticals NV(爱尔兰)和 Glenmark Pharmaceuticals(孟买)的子公司 Glenmark Specialty SA 宣布签署分销和许可协议,在南非和欧洲分销 Winlevi(1% clascoterone 乳膏)。协议规定,Glenmark 将获得在 15 个欧盟国家(萨宾、保加利亚、捷克共和国、丹麦、芬兰、法国、匈牙利、冰岛、荷兰、挪威、波兰、葡萄牙、罗马尼亚、斯洛伐克和瑞典)以及南非和英国通过 Cosmo 子公司 Cassiopea 销售 Winlevi 的独家权利。
- 2023 年 10 月,Crown Laboratories 旗下子公司 Crown Therapeutics 在其经皮肤科医生认可且屡获殊荣的 PanOxyl 系列中添加了两款新的 PanOxyl 产品——含 2% 水杨酸的 PanOxyl 净化去角质剂和 0.1% 的 PanOxyl 阿达帕林凝胶。2023 年 9 月,Sun Pharmaceutical Industries Limited 的全资子公司 Sun Pharma Canada Inc. 宣布 WINLEVI(clascoterone 乳膏,1% w/w)在加拿大上市。对于 12 岁及以上的患者,WINLEVI 是第一个也是唯一一个推荐用于局部治疗寻常痤疮或痤疮的雄激素受体抑制剂。
竞争格局和重点公司:
Teva Pharmaceutical Industries Ltd、Mayne Pharma Group Ltd、Almirall SA、Johnson & Johnson、Sun Pharmaceutical Industries Ltd、Bausch Health Companies Inc、Centro Internacional de Cosmiatria SA de CV、Galderma SA、Pfizer Inc.、GSK Plc、Viatris Inc、Somar Sapi De CV、Carnot Technologies 和 Italmex SA 是痤疮药物市场报告中介绍的几家主要公司。这些公司专注于开发和采用新技术、改进现有产品以及扩大其地理覆盖范围以满足全球日益增长的消费者需求。
- Historical Analysis (2 Years), Base Year, Forecast (7 Years) with CAGR
- PEST and SWOT Analysis
- Market Size Value / Volume - Global, Regional, Country
- Industry and Competitive Landscape
- Excel Dataset
Report Coverage
Revenue forecast, Company Analysis, Industry landscape, Growth factors, and Trends
Segment Covered
This text is related
to segments covered.
Regional Scope
North America, Europe, Asia Pacific, Middle East & Africa, South & Central America
Country Scope
This text is related
to country scope.
Frequently Asked Questions
Acne is a common skin condition characterized by the presence of comedones (blackheads and whiteheads), papules, pustules, nodules, and cysts on the skin, typically occurring on the face, neck, chest, back, and shoulders. It is primarily caused by factors such as excess oil production, clogged hair follicles, bacteria, and inflammation. Acne can vary in severity, ranging from mild occasional breakouts to severe, persistent conditions that can lead to scarring and psychological distress. Various medications and treatments are available to manage acne effectively.
Key factors driving the market growth are increasing prevalence of severe acne problems and launch of novel drugs.
The acne medication market is expected to be valued at US$ 11,802.29 million in 2030.
The acne medication market majorly consists of the players, including Teva Pharmaceutical Industries Ltd, Mayne Pharma Group Ltd, Almirall SA, Johnson & Johnson, Sun Pharmaceutical Industries Ltd, Bausch Health Companies Inc, Centro Internacional de Cosmiatria SA de CV, Galderma SA, Pfizer Inc., GSK Plc, Viatris Inc, Somar Sapi De CV, Carnot Technologies, and Italmex SA.
The acne medication market was valued at US$ 7,774.56 million in 2022.
Retinoids, which can be only bought with a doctor's prescription, contain vitamin A as a primary ingredient; they function similarly to retinol but they are far more potent and more successful in treating acne. Retinoids are available as oral capsules and topical therapies. Tretinoin, adapalene, and isotretinoin are well-known retinoids; the oral formulation of isotretinoin is sometimes referred to as Roaccutane. Retinoids are frequently prescribed in dosages of 0.1–1% for topical applications and 0.5–1 mg for oral applications per kilogram of patient weight.
The acne medication market is segmented into retail stores, pharmacies and drug stores, and others based on mode. In 2022, the pharmacies and drug stores segment held a larger market share. With their accessibility, privacy, and affordability (compared to private physicians), pharmacies and drug stores are vital sources of health services, supplies, and knowledge.
Based on type, the global acne medication market is classified into prescription medicines and over-the-counter medicines. The prescription medicines segment held a largest acne medication market share in 2022.
The topical medication segment held the largest share of the acne medication market in 2022. The same segment is further anticipated to record a significant CAGR in the market from 2022 to 2030.
Trends and growth analysis reports related to Life Sciences : READ MORE..
The List of Companies - Acne Medication Market
- Teva Pharmaceutical Industries Ltd
- Mayne Pharma Group Ltd
- Almirall SA
- Johnson & Johnson
- Sun Pharmaceutical Industries Ltd
- Bausch Health Companies Inc
- Centro Internacional de Cosmiatria SA de CV
- Galderma SA, Pfizer Inc.
- GSK Plc, Viatris Inc
- Somar Sapi De CV
- Carnot Technologies
- Italmex SA
The Insight Partners performs research in 4 major stages: Data Collection & Secondary Research, Primary Research, Data Analysis and Data Triangulation & Final Review.
- Data Collection and Secondary Research:
As a market research and consulting firm operating from a decade, we have published and advised several client across the globe. First step for any study will start with an assessment of currently available data and insights from existing reports. Further, historical and current market information is collected from Investor Presentations, Annual Reports, SEC Filings, etc., and other information related to company’s performance and market positioning are gathered from Paid Databases (Factiva, Hoovers, and Reuters) and various other publications available in public domain.
Several associations trade associates, technical forums, institutes, societies and organization are accessed to gain technical as well as market related insights through their publications such as research papers, blogs and press releases related to the studies are referred to get cues about the market. Further, white papers, journals, magazines, and other news articles published in last 3 years are scrutinized and analyzed to understand the current market trends.
- Primary Research:
The primarily interview analysis comprise of data obtained from industry participants interview and answers to survey questions gathered by in-house primary team.
For primary research, interviews are conducted with industry experts/CEOs/Marketing Managers/VPs/Subject Matter Experts from both demand and supply side to get a 360-degree view of the market. The primary team conducts several interviews based on the complexity of the markets to understand the various market trends and dynamics which makes research more credible and precise.
A typical research interview fulfils the following functions:
- Provides first-hand information on the market size, market trends, growth trends, competitive landscape, and outlook
- Validates and strengthens in-house secondary research findings
- Develops the analysis team’s expertise and market understanding
Primary research involves email interactions and telephone interviews for each market, category, segment, and sub-segment across geographies. The participants who typically take part in such a process include, but are not limited to:
- Industry participants: VPs, business development managers, market intelligence managers and national sales managers
- Outside experts: Valuation experts, research analysts and key opinion leaders specializing in the electronics and semiconductor industry.
Below is the breakup of our primary respondents by company, designation, and region:
Once we receive the confirmation from primary research sources or primary respondents, we finalize the base year market estimation and forecast the data as per the macroeconomic and microeconomic factors assessed during data collection.
- Data Analysis:
Once data is validated through both secondary as well as primary respondents, we finalize the market estimations by hypothesis formulation and factor analysis at regional and country level.
- Macro-Economic Factor Analysis:
We analyse macroeconomic indicators such the gross domestic product (GDP), increase in the demand for goods and services across industries, technological advancement, regional economic growth, governmental policies, the influence of COVID-19, PEST analysis, and other aspects. This analysis aids in setting benchmarks for various nations/regions and approximating market splits. Additionally, the general trend of the aforementioned components aid in determining the market's development possibilities.
- Country Level Data:
Various factors that are especially aligned to the country are taken into account to determine the market size for a certain area and country, including the presence of vendors, such as headquarters and offices, the country's GDP, demand patterns, and industry growth. To comprehend the market dynamics for the nation, a number of growth variables, inhibitors, application areas, and current market trends are researched. The aforementioned elements aid in determining the country's overall market's growth potential.
- Company Profile:
The “Table of Contents” is formulated by listing and analyzing more than 25 - 30 companies operating in the market ecosystem across geographies. However, we profile only 10 companies as a standard practice in our syndicate reports. These 10 companies comprise leading, emerging, and regional players. Nonetheless, our analysis is not restricted to the 10 listed companies, we also analyze other companies present in the market to develop a holistic view and understand the prevailing trends. The “Company Profiles” section in the report covers key facts, business description, products & services, financial information, SWOT analysis, and key developments. The financial information presented is extracted from the annual reports and official documents of the publicly listed companies. Upon collecting the information for the sections of respective companies, we verify them via various primary sources and then compile the data in respective company profiles. The company level information helps us in deriving the base number as well as in forecasting the market size.
- Developing Base Number:
Aggregation of sales statistics (2020-2022) and macro-economic factor, and other secondary and primary research insights are utilized to arrive at base number and related market shares for 2022. The data gaps are identified in this step and relevant market data is analyzed, collected from paid primary interviews or databases. On finalizing the base year market size, forecasts are developed on the basis of macro-economic, industry and market growth factors and company level analysis.
- Data Triangulation and Final Review:
The market findings and base year market size calculations are validated from supply as well as demand side. Demand side validations are based on macro-economic factor analysis and benchmarks for respective regions and countries. In case of supply side validations, revenues of major companies are estimated (in case not available) based on industry benchmark, approximate number of employees, product portfolio, and primary interviews revenues are gathered. Further revenue from target product/service segment is assessed to avoid overshooting of market statistics. In case of heavy deviations between supply and demand side values, all thes steps are repeated to achieve synchronization.
We follow an iterative model, wherein we share our research findings with Subject Matter Experts (SME’s) and Key Opinion Leaders (KOLs) until consensus view of the market is not formulated – this model negates any drastic deviation in the opinions of experts. Only validated and universally acceptable research findings are quoted in our reports.
We have important check points that we use to validate our research findings – which we call – data triangulation, where we validate the information, we generate from secondary sources with primary interviews and then we re-validate with our internal data bases and Subject matter experts. This comprehensive model enables us to deliver high quality, reliable data in shortest possible time.